company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1617000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4173000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5790000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5790000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5790000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,0.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5790000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5790000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,326000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6116000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.7
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.7
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1652726.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q1,2014-01-01,2014-03-31,2015-05-15 16:23:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.7
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1807000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4381000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6188000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6188000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6187000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-5000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6192000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6192000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,1577000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7769000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-4.57
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-4.57
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1700517.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q2,2014-04-01,2014-06-30,2015-08-12 16:54:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-4.57
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2869000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6601000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9470000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9470000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9467000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-1000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9468000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9468000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,391000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9859000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.5
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.5
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19581624.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 15:51:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.5
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3417000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8945000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12362000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12362000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12358000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-3000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12361000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12361000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12361000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21600000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,7.1
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21600000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,7.1
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21574347.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,7.1
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3997000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12900000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16897000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16897000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,21000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,21000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16876000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,5000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16871000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16871000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16871000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25600000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.66
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25600000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.66
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25655883.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q1,2015-01-01,2015-03-31,2016-05-06 16:18:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.66
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6456000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18603000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25059000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25059000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,41000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,41000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25018000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-9000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25027000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25027000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25027000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27800000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.9
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27800000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.9
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27860332.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 06:46:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.9
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6604000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17478000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24082000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24082000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,53000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,53000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24029000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-6000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24035000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24035000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24035000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28600000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.84
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28600000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.84
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28737743.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 08:31:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.84
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8236000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20376000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28612000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-28612000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,63000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,63000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-28549000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-13000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-28562000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-28562000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-28562000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27800000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27800000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27778288.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7133000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23581000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30714000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-30714000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,175000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,175000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30539000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-4000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30543000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30543000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30543000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,31500000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.97
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,31500000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.97
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,31643216.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 19:01:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.97
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8910000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,26096000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35006000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35006000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,266000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,266000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-34740000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-7000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34747000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34747000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-34747000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,32200000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.08
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,32200000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.08
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,32062298.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 16:16:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.08
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8989000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29075000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38064000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38064000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,275000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,275000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-37789000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-7000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-37796000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-37796000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-37796000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,32900000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.15
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,32900000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.15
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,32975897.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 07:46:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.15
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14375000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,42004000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,56379000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-56379000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,495000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,495000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-55884000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-17000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-55901000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-55901000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-55901000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33500000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.55
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33500000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.55
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33492795.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.55
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12280000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,45200000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,57480000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-57480000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,707000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,707000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-56773000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-5000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-56778000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-56778000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-56778000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37400000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.52
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37400000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.52
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37269148.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 07:17:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.52
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14954000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,55900000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,70854000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-70854000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,672000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,672000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-70182000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-20000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-70202000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-70202000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-70202000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37300000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.88
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37300000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.88
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37361129.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q2,2017-04-01,2017-06-30,2018-08-07 07:32:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.88
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16087000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,58286000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,74373000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-74373000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,677000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,677000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-73696000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-23000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-73719000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-73719000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-73719000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37470912.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.97
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37470912.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.97
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37470912.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 07:55:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.97
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,19557000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,50891000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,70448000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-70448000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1043000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1043000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-69405000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-16000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-69421000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-69421000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-69421000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38100000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.72
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38100000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.72
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38113678.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.72
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28849000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,49270000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,78119000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-78119000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3529000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3529000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-74590000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-8000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-74598000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-74598000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-74598000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44325371.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.68
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44325371.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.68
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,44325371.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 07:16:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.68
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,90000000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,90000000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,90000000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,43167000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,68980000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,112147000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22147000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5137000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5137000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17010000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,32000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16978000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16978000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16978000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47200000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.36
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47200000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.36
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46541716.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 07:16:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,53693000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,75052000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,128745000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-128745000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5817000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5817000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-122928000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,10000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-122918000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-122918000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-122918000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.63
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.63
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46706770.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 07:16:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.63
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,273000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,273000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,273000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,75695000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,88805000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,164500000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-164227000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5851000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5851000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-158376000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-12000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-158388000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-158388000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-158388000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46100000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.41
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46100000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.41
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46121194.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.41
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,465000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,465000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,465000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,83919000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,86398000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,170317000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-169852000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,6442000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6442000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-163410000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,4000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-163406000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-163406000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-163406000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48500000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.37
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48500000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.37
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48491834.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 16:21:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.37
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1227000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1227000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,44000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,44000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1183000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,88227000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,89059000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,177286000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-176457000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8220000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,8220000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-168237000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,16000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-168221000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-168221000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-168221000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51300000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.28
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51300000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.28
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51257640.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 07:16:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.28
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3570000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3570000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,137000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,137000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3433000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,88502000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,102108000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,190610000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-187177000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,7227000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,7227000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-179950000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-8000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-179958000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-179958000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-179958000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.48
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51700000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.48
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51704687.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 07:16:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.48
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1606000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1606000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,219000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,219000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1387000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,85129000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,91250000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,176379000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-174638000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5915000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5915000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-168723000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,70000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-168653000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-168653000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-168653000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50800000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.25
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50800000.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.25
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50833837.0
SAGE Therapeutics Inc,SAGE,5493000JX4BJS9W6CN35,0001597553,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.25
